Comparison between efficacy of topical 1% ivermectin and topical 5% permethrin in the treatment of scabies
DOI:
https://doi.org/10.66344/jpad.31.4.2021.1792Abstract
Abstract:
Background: To compare the efficacy of topical permethrin 5% and topical ivermectin 1% in the treatment of scabies.
Methodology: Design: Experimental study/ Randomized control Trial study. Setting: Dermatology Department of Lahore General Hospital, Lahore. Duration: 31st January 2019 to 31st January’ 2020. Total 200 patients of 18-70 years age from both genders were enrolled, and divided into 2 groups: topical Ivermectin1% and topical permethrin 5% was given to group A and group B, respectively. The efficacy was noted by following the cases after every 2 weeks in outpatient department during 4-week treatment.
Results: Mean age of the patients from group A was 46.50±15.26 years, while from group B was 42.46±14.42 years. Male to female ratio was 0.47:1. Out of 200 patients, the remission was achieved in 188(94%) patients out of which 97 (97%) were from Permethrin group and 91(91%) were from Ivermectin group. The difference was statistically insignificant (p-value=0.074).
Conclusion: Topical management of scabies with ivermectin 1% and permethrin 5% is equally beneficial.
Key Words: Ivermectin, Permethrin, Efficacy, Scabies
Downloads
Published
Issue
Section
License
Copyright (c) 2022 AAISHA USMAN, DR ATIF SHEHZAD, MUHAMMAD SHAHID, DR ZAHEER SALEEM, DR ANEELA KHAWAJA, DR ABEER
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
